On the other hand, insulin responses are decreased in all ESRD patients and fasting concentrations of glucagon are increased in these patients, since progression of renal disease is involved with metabolic dysregulation such as impairments in the glucose metabolism and increased risk of diabetes, as a result, the beta cells in the patients with ESRD are unable to respond to increased glucose by insulin secretion. Here, INS is linked to diabetes mellitus.